FHIR in Pharma Regulatory Affairs: What Teams Need to Know
FHIR (Fast Healthcare Interoperability Resources) is moving into pharma regulatory affairs because regulators and industry need structured, machine-readable health and product data instead of documents. Today it shows up in three main places: structured product information, the exchange of real-world data from health records, and clinical research workflows that pull data directly from care systems.
This guide explains where FHIR fits in regulatory work, where it does not replace existing submission standards, and how regulatory and data teams can prepare without rebuilding everything they have.
Why FHIR Is Reaching Regulatory Affairs Now
Regulatory affairs has always been document-heavy. Labels, product dossiers, safety reports and study data travel as files that humans read and re-key. That model is slow and error-prone, and it struggles with the volume of data that modern drug development produces.
FHIR, the HL7 standard for exchanging health data through modern web interfaces, offers a different model: discrete, coded resources that software can read directly. It was built for clinical care, but its reach has grown. Hospitals and electronic health record vendors in many countries now expose FHIR interfaces, which means the real-world data regulators increasingly ask about is often available in FHIR form first.
At the same time, regulators are pushing for structured data. In Europe, the European Medicines Agency and its network partners have agreed a common standard for electronic product information (ePI) built on FHIR. Product data services that support the ISO IDMP standards use FHIR-based interfaces. And guidance on using health record data as real-world evidence puts weight on data reliability and traceability, which structured standards help demonstrate.
Where FHIR Fits in Regulatory Work
Structured Product Information
Electronic product information turns the package leaflet and summary of product characteristics into structured content. Instead of a PDF, each section and data element becomes a FHIR resource that can be updated, translated and reused. For regulatory teams, that means labeling changes can flow through systems more consistently, and downstream users such as pharmacies and apps can consume current information directly.
Product and Substance Master Data
IDMP standards describe medicinal products, substances, organizations and referentials in a consistent way. FHIR resources for medicinal product definitions give these concepts a common exchange format between companies and regulators, which reduces the reconciliation work that comes with every variation.
Real-World Data From Health Records
When a regulatory question depends on real-world evidence, the source data often sits in electronic health records. FHIR gives a standard way to extract that data with codes and context intact. It does not, by itself, make the data fit for regulatory use; quality, provenance and fitness for purpose still need to be shown.
Clinical Research Workflows
The HL7 Vulcan accelerator brings pharma, regulators and technology groups together to apply FHIR to clinical research, including moving data from care records into trial systems and representing study definitions. CDISC and HL7 have also published joint guidance on mapping FHIR data to CDISC standards, which matters because submission datasets still follow CDISC.
Safety and Pharmacovigilance
Adverse event reporting already relies on structured standards such as ICH E2B. FHIR is not a replacement for those reporting formats, but it can help safety teams in two ways. It offers a consistent route for pulling supporting clinical context, such as medications and lab results, from care systems when a case needs follow-up. And it gives signal detection teams a standard way to reach real-world data sources when they need to check whether a suspected signal appears in routine care. In both cases the value comes from consistent codes and timestamps, which make it easier to show where each data point came from.
What FHIR Does Not Replace
FHIR is an exchange standard, not an analysis model and not a submission format. Three boundaries are worth keeping clear.
- Submission datasets: study data submitted to regulators continues to follow CDISC standards such as SDTM and ADaM. FHIR can feed those datasets, not stand in for them.
- Population analysis: FHIR is designed around individual patient records and transactions. For large observational studies, data is usually transformed into an analysis model such as the OMOP CDM.
- Document submissions: the eCTD structure for dossiers remains the vehicle for most submissions, even as more of its content becomes structured.
The practical picture is a pipeline: FHIR to move data out of care systems, OMOP to analyze it at scale, CDISC to submit it. The comparison of OMOP vs FHIR covers that split in more depth.
Comparing the Standards Regulatory Teams Meet
| Standard | Main purpose | Where regulatory teams meet it | Typical owner |
|---|---|---|---|
| FHIR | Exchanging health and product data between systems | ePI, IDMP data exchange, health record extraction | Regulatory operations, data engineering |
| OMOP CDM | Analyzing observational data across sources | Real-world evidence studies, feasibility | Epidemiology, real-world evidence teams |
| CDISC SDTM and ADaM | Standardized study data for submission | Clinical trial submissions | Biostatistics, clinical data management |
| eCTD | Structuring the regulatory dossier | Marketing applications and variations | Regulatory affairs |
| ISO IDMP | Identifying medicinal products consistently | Product master data, pharmacovigilance | Regulatory information management |
The Data Access Problem Behind Real-World Evidence
The hardest part of using FHIR-sourced data for regulatory questions is rarely the format. It is access. Hospitals and national programs hold the records, and they are often unable or unwilling to send patient-level data to a sponsor. Pooling data centrally also creates privacy risk that grows with every copy, and cross-border rules can block it outright.
A federated approach solves this differently. Each data custodian converts its records, often arriving through FHIR, into a common model inside its own Trusted Research Environment (TRE). The sponsor’s approved analysis runs where the data sits, and only aggregate results that pass output checks come back. Data never leaves the source, yet the sponsor gets evidence from several custodians at once, with a full audit trail of what was run and what was released.
That audit trail matters for regulators. Being able to show exactly which data, which code and which version produced a result supports the reliability and traceability that real-world evidence guidance asks for. A Federated Trusted Research Environment makes this repeatable across studies.
Common Pitfalls
Teams new to FHIR in a regulatory setting tend to hit the same problems.
- Treating FHIR as an analysis model. Running population studies directly on FHIR resources tends to be slow and hard to reproduce. Transform first.
- Ignoring local profiles. FHIR implementations differ by country and vendor through profiles and extensions. A mapping built for one source may not work for the next.
- Losing terminology. Codes from SNOMED CT, LOINC or local systems must be kept and mapped, not flattened into text.
- Skipping provenance. If you cannot show which system and version produced a value, its regulatory weight drops.
- Starting too big. Programs that try to convert every source at once stall. Pick one question and one source first.
How to Prepare
- Map where FHIR already touches you. List ePI, IDMP and real-world data projects, and note which partners already offer FHIR interfaces.
- Separate exchange from analysis. Plan FHIR for moving data and a common analysis model for studying it, with documented mappings between them.
- Keep CDISC in the loop. Where trial data originates in care systems, use published FHIR to CDISC mappings so submission datasets stay consistent.
- Build provenance in. Record source system, extraction date, mapping version and transformation steps for every dataset that may support a regulatory decision.
- Choose access models custodians accept. Analysis in place often opens doors that data transfer requests close.
Skills and Team Structure
FHIR work in regulatory settings sits between disciplines. Regulatory operations understands the submission rules, data engineers understand the interfaces, and real-world evidence teams understand what makes data fit for a study. Successful programs give one owner responsibility for the end-to-end pipeline, keep a shared catalog of mappings and terminologies, and involve quality assurance early so validation is designed in rather than added at the end. Small pilots on a single use case, such as one ePI update or one real-world evidence feasibility question, build the shared vocabulary faster than a large program plan.
Frequently asked questions
What is FHIR used for in regulatory affairs?
It is used for structured product information such as ePI, for exchanging product master data under IDMP, for extracting real-world data from health records and in clinical research workflows that draw on care systems.
Does FHIR replace CDISC for submissions?
No. Submission datasets still follow CDISC standards. FHIR can feed those datasets, and joint HL7 and CDISC mapping guidance helps keep them consistent.
Is FHIR or OMOP better for real-world evidence?
They do different jobs. FHIR is best for moving data out of care systems; OMOP is best for analyzing large observational datasets. Many pipelines use both.
What is ePI and how does it relate to FHIR?
Electronic product information is the structured, digital version of product labeling. The common standard agreed in Europe is built on FHIR.
Can sponsors use hospital FHIR data without receiving a copy?
Yes. In a federated Trusted Research Environment, approved analysis runs where the data is held and only checked aggregate results are returned.
How should a regulatory team start with FHIR?
Start by mapping existing projects that touch FHIR, then run a small pilot on one use case with clear provenance and validation built in.